NEW TREATMENT APPROACHES TO PREVENT PREMATURE RUPTURE OF MEMBRANES IN PREGNANT WOMEN WITH VARICOSE DISEASE

Year 2018, Volume: 5 Issue: 1, 9 - 13, 25.02.2018

Vinisha Tekwani Varahabhatla Vamsi Gaidai Nataliya

Abstract

Aims: To investigate modern methods to prevent premature rupture of membranes by the use of chlorhexidine in
pregnant women with varicose disease.

Methods: The data of 39 pregnant women with varicose disease, who delivered between 2014 and 2016 at Maternity
Hospital No. 3, Zaporozhye were analyzed using SPSS software. Patients were divided in 3 groups according to
their medical history, complications during pregnancy, childbirth and postpartum period. The 1st group consisted
of 13 pregnant women who did not receive prenatal vaginal douching with chlorhexidine; the 2nd group consisted
of 13 patients with varicose disease, who received douching of birth canal with vaginal suppositories with chlorhexidine
1 time per day for 10 days before their delivery, but did not undergo a rehabilitation at the sanatorium; and the
3rd group had 13 pregnant women who received sanatorium rehabilitation at ‘‘Veliki lug’’ during the II. trimester of
their pregnancy with the course of 1 chlorhexidine suppository per day for 10 days before delivery.

Results:In the 1st group, the percentage of premature death was 61.5%; anemia and significant ultrasound markers
were present in 46.2%; the percentage for the presence of hematometra was 38.5%; premature rupture of membranes,
anomalies of labor and polyhydroamniosis were 30.8%; chorioamnionitis 15.4%; and intrauterine infection of
fetus was 7.7%. In the 2nd group, anemia was present in 35%, 23.1% showed anomalies of labor; premature rupture
of membranes, ultrasound markers, premature death, and hematometra were present in 15.4%. Whereas in the 3rd
group, anemia and anomalies of labor were present in 15.4%, premature rupture of the membranes and premature
death were present in 7.7% of the patients.

Conclusion: With its broad antibacterial and antiviral effect, chlorhexidine in antiseptic form was found to be
beneficial and it is found to promote the restoration of the vaginal microflora.

Keywords

Pregnancy, infection, membrane

References

• 1. Aaron BC, Julian NR, Errol RN et al. Contemporary diagnosis and management of preterm premature rupture of membranes. Rev Obstet Gynecol 2008;1(1):11– 22.
• 2. Mackeen AD, Seibel-Seamon J, Grimes-Dennis J et al. Tocolytics for preterm premature rupture of membranes. Cochrane Database Syst Rev 2011;5(10):CD007062.
• 3. Cunningham F. Abnormal Labor. In: Cunningham F, Leveno KJ, Bloom SL et al, editors. Williams Obstetrics. New York: McGraw-Hill Education; 2014.
• 4. Roman AS. Late Pregnancy Complication, section: premature rupture of membranes. In: Decherney AH, Nathan L, Laufer N, editors. Current Diagnosis & Treatment: Obstetrics & Gynecology. New York: McGraw-Hill Medical; 2013.
• 5. Sarah N, Dan KK, Freddie B et al. Practice bulletins No. 139: premature rupture of membranes. Obstet Gynecol 2013;122(4):918-30.
• 6. Nakubulwa S, Kaye DK, Bwanga F et al. Genital infections and risk of premature rupture of membranes in Mulago Hospital, Uganda: a case-control study. BMC Res Notes 2015;16(8):573.
• 7. Beckmann C. Premature Rupture of Membranes. In: Beckmann CRB, Ling FW, Barzansky BM, editors. Obstetrics and Gynecology. Baltimore: Lippincott; 2010.p.13–6.
• 8. World Health Organization. WHO guidelines on hand hygiene in health Care. WHO, 2009. Available from URL:http://www.who.int/gpsc/5may/tools/9789241597906/en/ (13 August 2012).
• 9. McClure EM, Goldenberg RL, Brandes N et al. The use of chlorhexidine to reduce maternal and neonatal mortality and morbidity in low-resource settings. International Journal of Gynecology and Obstetrics 2007;97(2):89–94.
• 10. World Health Organization. Model list of essential medicines for children, 3rd list. Geneva: WHO; March 2011.
• 11. World Health Organization Expert Committee on Essential Medicines. The selection and use of essential medicines. Geneva: WHO; 2009.
• 12. ZA Lupinskaya. Endothelium of blood vessels-the main regulator of local blood flow. Vest-nik KRSU 2003:34-7.
• 13. Lutsenko NS, Evtereva IA. Sanatorium-and-spa treatment as a factor of optimizing the out-come of pregnancy. Zaporozhye Medical Journal 2006:91-4.
• 14. Lutsenko NS, Gayday NV, Shapran NF. Ways to optimize hemodynamics in the fetoplacen-tal pool, as a factor in influencing the perinatal outcome. Porto Biomed J 2017;2(5):245.
• 15. Makarov OV, Kozlov LV. Ways of preventing perinatal morbidity and mortality in preterm pregnancy. Women’s Health 2012;72:91-5.
• 16. Goldenberg RL, McClure EM, Saleem S et al. Use of vaginally administered chlorhexidine during labor to improve pregnancy outcomes. Obstet Gynecol 2006;107(5):1139–46.
• 17. Taha TE, Biggar R, Broadhead RL et al. Effect of cleansing the birth canal with antiseptic solution on maternal and newborn morbidity and mortality in Malawi: clinical trial. BMJ 1997;315:216–9.
• 18. Bakr AF, Karkour T. Effect of predelivery vaginal antisepsis on maternal and neonatal morbidity and mortality in Egypt. J Womens Health 2005;14:496–501.
• 19. L C Mullany, J M Tielsch, G L Darmstadt et al. Topical applications of chlorhexidine to the umbilical cord for prevention of omphalitis and neonatal mortality in southern Nepal: a communi-ty-based, cluster-randomised trial. The Lancet 2006;367(9514):910-8.
• 20. Lumbiganon P, Thinkhamrop J, Thinkhamrop B et al. Vaginal chlorhexidine during labour for preventing maternal and neonatal infections (excluding Group B Streptococcal and HIV). Cochrane Database Syst Rev 2004;18(4):CD004070.
• 21. Lumbiganon P, Thinkhamrop J, Thinkhamrop B et al. Vaginal chlorhexidine during labour for preventing maternal and neonatal infections (excluding Group B Streptococcal and HIV). Cochrane Database Syst Rev 2014;14(9):CD004070.
• 22. Christensen KK, Christensen P, Dykes A et al. Chlorhexidine for the prevention of neonatal colonization with group B streptococci. I. In vitro effect of chlorhexidine on group B streptococ-ci. European Journal of Obstetrics & Gynecology and Reproductive Biology 1983;16:157-65.
• 23. Stade B, Shah V, Ohlssen A. Vaginal chlorhexidine during labour to prevent early-onset neonatal group B streptococcal infection. Cochrane Database Syst Rev 2004;3:CD003520.
• 24. Hemani ML, Lepor H. Skin preparation for the prevention of surgical site infection: which agent is best? Reviews in Urology 2009;11(4):190-5.
• 25. Shubair M, Stanek R, White S et al. Effects of chlorhexidine gluconate douche on normal vaginal flora. Gynecol Obstet Invest 1992;34(4):229-33.